跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VYVANSE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VYVANSE
Authorized
STANDARD
VYVANSE
takeda canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f1aa1c4ca94c41ce
Company
takeda canada inc
Type
Standard
Approval Details
Approval Id
f1aa1c4ca94c41ce
Drug Approval Canada Name
VYVANSE
Product Name
VYVANSE
Status
Marketed
Status Date
2021-11-02
Original Market Date
2019-08-06
Din
02490242
Drug Class
Human
Dosage Form
Tablet (Chewable)
Route Of Administration
Oral
Schedule
Schedule G (CDSA I)
Ahfs
28:20.04
Atc Original
N06BA12 LISDEXAMFETAMINE
Atc Name
n 06 ba 12
Aig Number
0152536001
Company Name
takeda canada inc
Company Address
3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3
Active Ingredients
LISDEXAMFETAMINE DIMESYLATE
30 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f1aa1c4ca94c41ce
Type
Standard
Back to Health Canada Approvals